Literature DB >> 16784894

Designing nonviral vectors for efficient gene transfer and long-term gene expression.

Dean A Jackson1, Stefan Juranek, Hans J Lipps.   

Abstract

Although the genetic therapy of human diseases has been conceptually possible for many years we still lack a vector system that allows safe and reproducible genetic modification of eukaryotic cells and ensures faithful long-term expression of transgenes. There is increasing agreement that vectors that are based exclusively on chromosomal elements, which replicate autonomously in human cells, could fulfill these criteria. The rational construction of such vectors is still hindered by our limited knowledge of the factors that regulate chromatin function in eukaryotic cells. This review sets out to summarize how our current knowledge of nuclear organization can be applied to the design of extrachromosomal gene expression vectors that can be used for human gene therapy. Within the past years a number of episomal nonviral constructs have been designed and their replication strategies, expression of transgenes, mitotic stability, and delivery strategies and the mechanisms required for their stable establishment will be discussed. To date, these nonviral vectors have not been used in clinical trials. Even so, many compelling arguments can be developed to support the view that nonviral vector systems will play a major role in future gene therapy protocols.

Entities:  

Mesh:

Year:  2006        PMID: 16784894     DOI: 10.1016/j.ymthe.2006.03.026

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  36 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 2.  Peptide-guided gene delivery.

Authors:  Molly E Martin; Kevin G Rice
Journal:  AAPS J       Date:  2007-02-09       Impact factor: 4.009

Review 3.  Matrices and scaffolds for DNA delivery in tissue engineering.

Authors:  Laura De Laporte; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2007-04-14       Impact factor: 15.470

Review 4.  Nanoparticle applications in ocular gene therapy.

Authors:  Xue Cai; Shannon Conley; Muna Naash
Journal:  Vision Res       Date:  2007-09-06       Impact factor: 1.886

5.  Intranuclear trafficking of episomal DNA is transcription-dependent.

Authors:  Joshua Z Gasiorowski; David A Dean
Journal:  Mol Ther       Date:  2007-07-31       Impact factor: 11.454

Review 6.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

7.  E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites.

Authors:  Alina Rabinovich; Victor X Jin; Roman Rabinovich; Xiaoqin Xu; Peggy J Farnham
Journal:  Genome Res       Date:  2008-10-03       Impact factor: 9.043

8.  Mechanistic Insight into Receptor-Mediated Delivery of Cationic-β-Cyclodextrin:Hyaluronic Acid-Adamantamethamidyl Host:Guest pDNA Nanoparticles to CD44(+) Cells.

Authors:  Vivek Badwaik; Linjia Liu; Dinara Gunasekera; Aditya Kulkarni; David H Thompson
Journal:  Mol Pharm       Date:  2016-02-22       Impact factor: 4.939

9.  Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver.

Authors:  Orestis Argyros; Suet Ping Wong; Constantinos Fedonidis; Oleg Tolmachov; Simon N Waddington; Steven J Howe; Marcello Niceta; Charles Coutelle; Richard P Harbottle
Journal:  J Mol Med (Berl)       Date:  2011-02-08       Impact factor: 4.599

10.  PDGF-A promoter and enhancer elements provide efficient and selective antineoplastic gene therapy in multiple cancer types.

Authors:  A Mishra; A K Ormerod; M L Cibull; B T Spear; S D Kraner; D M Kaetzel
Journal:  Cancer Gene Ther       Date:  2008-11-07       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.